title: Virus-inhibiting surgical glove to reduce the risk of infection by enveloped viruses.
abstract: Needle puncture and other accidents that occur during surgery and other procedures may lead to viral infections of medical personnel, notably by hepatitis C (HCV) and human immunodeficiency virus (HIV), now that hepatitis B can be prevented by vaccination. A new surgical glove called G-VIR, which contains a disinfecting agent for enveloped viruses, has been developed. Herpes simplex type 1 (HSV) was used as a standard enveloped virus in both in vitro and in vivo tests of the virucidal capacity of the glove. Bovine viral diarrhea virus (BVDV) and feline immunodeficiency virus (FIV) were used as models for HCV and HIV, respectively. For in vitro study, a contaminated needle was passed through a glove and residual virus was titrated; for in vivo studies, animals were stuck with a contaminated needle through a glove. Despite variation in virus enumeration inherent in the puncture technique, statistical evaluation showed that infection was reproducibly and substantially reduced by passage through the virucidal layer. For BVDV, the amount of virus passing through the virucidal glove was reduced in 82% of pairwise comparisons with control gloves that lacked the virucidal agent; when plaque counts were adjusted to a common dilution, the median count for the virucidal glove was on the average reduced >10-fold. In experiments in which the proportion of wells infected with FIV was measured, the ratio of TCID(50) values (control glove to G-VIR) was >15, and probably much higher. For HSV, the amount of virus passing through the virucidal glove was reduced in 81% of comparisons with control gloves; the median of adjusted plaque counts was reduced on the average approximately eightfold or ninefold. In vivo tests with FIV and HSV in cats and mice, respectively, found smaller percentage reductions in infection than the in vitro tests but confirmed the virucidal effect of the gloves.
authors.affiliation: Hôtel Dieu, Laboratoire Central de Microbiologie, Paris, France.
authors.forename: Fernand
authors.initials: F
authors.lastname: Bricout
authors.forename: Anne
authors.initials: A
authors.lastname: Moraillon
authors.forename: Philippe
authors.initials: P
authors.lastname: Sonntag
authors.forename: Pierre
authors.initials: P
authors.lastname: Hoerner
authors.forename: William
authors.initials: W
authors.lastname: Blackwelder
authors.forename: Stanley
authors.initials: S
authors.lastname: Plotkin
mesh_terms: D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology*; D002415:Cats; D001908:Diarrhea Viruses, Bovine Viral / Q000187:drug effects / Q000254:growth & development; D004195:Disease Models, Animal; D004311:Double-Blind Method; D005932:Gloves, Surgical; D015658:HIV Infections / Q000517:prevention & control; D006526:Hepatitis C / Q000517:prevention & control; D006801:Humans; D016089:Immunodeficiency Virus, Feline / Q000187:drug effects / Q000254:growth & development; D051379:Mice; D008819:Mice, Nude; D016602:Needlestick Injuries; D018139:Simplexvirus / Q000187:drug effects / Q000254:growth & development; D014759:Viral Envelope Proteins; D014777:Virus Diseases / Q000517:prevention & control* / Q000635:transmission / Q000821:virology; D014780:Viruses / Q000187:drug effects* / Q000254:growth & development
chemical_list: D000998:Antiviral Agents; D014759:Viral Envelope Proteins